Venture Capital for German Biotech Firms Expected to Plummet in 2025

Venture capital for German biotech companies is projected to decline significantly in 2025. This funding scarcity makes it difficult for firms to secure substantial investments, potentially leading to innovation moving abroad and impacting Germany's position as a business location.